Description

Established in 1958 and headquartered in Seoul, South Korea, Daewon Pharmaceutical Co., Ltd. is a well-regarded pharmaceutical enterprise specializing in the development, manufacturing, and distribution of a comprehensive range of medications and medical supplies within the South Korean market. Its extensive product portfolio targets diverse therapeutic fields, encompassing cardiovascular, respiratory, anti-infective, oncology, and neuropsychiatric conditions. Key offerings include Oramin-F Soft Cap, a notable multivitamin; Pelubi Tablet, an NSAID specifically formulated for pain management; Freefol-MCT Inj., a microemulsion propofol designed to prevent exogenous bacterial infections; Megex-I Susp, a medication that supports the nutritional needs of cancer patients experiencing subalimentation; Trigel Susp, an effective treatment for gastritis and duodenal ulcers; and Renamezin Cap, a spherical carbonaceous adsorbent for managing chronic kidney disease. Furthermore, Daewon Pharmaceutical extends its global footprint by exporting its products to approximately 45 countries, predominantly across Asia, Central and South America, and the Middle East.